Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

We recently published 10 Stocks That Vanished in Value Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

The Portnoy Law Firm advises Hims & Hers Health, Inc. ("Hims & Hers Health" or the "Company") (NYSE: HIMS) investors of a class action representing investors that bought securities between April 29, ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Shares of Hims & Hers (HIMS) are down 92c, or 2%, to $45.09 in pre-market trading after GoodRx (GDRX) announced that all strengths of Ozempic and Wegovy pens are available to eligible self-paying ...

Ten large-cap stocks, including CRWV, COHR & AMZN, were the worst performers last week. Weak results, downgrades, and FTC ...

Truist lowered the firm’s price target on Hims & Hers to $37 from $48 and keeps a Hold rating on the shares. The firm’s intra-quarter Truist Card ...